Philip Thompson

Philip Thompson

Auto-generated profile, based on publicly available information

Philip Thompson

Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
FTFrancesco Paolo Tambaro
Francesco Paolo Tambaro
HSHarjeet Singh
Harjeet Singh
EJEmily Jones
Emily Jones
MRMichael Rytting
Michael Rytting
Kris MahadeoKris Mahadeo
Kris Mahadeo
WWWilliam G. Wierda
William G. Wierda

1 February 2021 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
AMAbhishek Maiti
Abhishek Maiti
CDCourtney Dinardo
Courtney Dinardo
Naval DaverNaval Daver
Naval Daver
CRCaitlin R. Rausch
Caitlin R. Rausch
FRFarhad Ravandi
Farhad Ravandi
MKMarina Konopleva
Marina Konopleva

2 July 2020 in Blood
Verified
Journal Article
Closed access
PTPhilip A. Thompson
Philip A. Thompson

14 May 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
CTConstantine Tam
Constantine Tam
PTPhilip A. Thompson
Philip A. Thompson
BTK inhibitors (BTKis) are established standards of care in multiple B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom macroglobulinemia. The first-generation BTKi ibrutinib demonstrated superiority over standard chemoimmunotherapy regimens in multiple randomized trials but is limited by cardiovascular side effects such as atrial fibrillation and hypertension. Second-generation BTKis have improved selectivity and demonstrate reduced rates of cardiovascular complications in 3 head-to-head ibrutinib studies. The emergence of BTK C481S mutation has led to the development of noncovalent, “reversible” BTKis, such as pirtobrutinib, which are agnostic to the C481S mutation. However, these inhibitors are associated with resistant mutations outside the C481 hot spot. These variant non-C481 mutations are of great clinical interest because some are shared among pirtobrutinib, zanubrutinib, and acalabrutinib, with potential implications for cross resistance and treatment sequencing. Finally, BTK protein degraders with in vitro activity against C481 and non-C481 mutations are currently in clinical development. Here, we review the evolution of therapeutic BTK-targeting and discuss future directions for clinical research.

28 November 2019 in Blood
Verified
Journal Article
Open access
PDF file
PTPhilip A. Thompson
Philip A. Thompson
JSJaya Srivastava
Jaya Srivastava
CPChristine Peterson
Christine Peterson
PSPaolo Strati
Paolo Strati
JJJeffrey L. Jorgensen
Jeffrey L. Jorgensen
WWWilliam G. Wierda
William G. Wierda
Thompson and colleagues report that detection of minimal residual disease using next-generation sequencing, which is 2 orders of magnitude more sensitive than flow cytometry, is a much better predictor of progression-free survival.

10 May 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
Nitin JainNitin Jain
Nitin Jain
JSJayastu Senapati
Jayastu Senapati
BTBeenu Thakral
Beenu Thakral
AFAlessandra Ferrajoli
Alessandra Ferrajoli
PTPhilip Thompson
Philip Thompson
WWWilliam G. Wierda
William G. Wierda
Richter transformation (RT) is a rare complication of chronic lymphocytic leukemia (CLL) that has dismal outcomes. Upregulation of PD-1/PD-L1 drives immunological evasion in patients with RT. We hypothesized that combining nivolumab, a PD-1 blocking antibody, with the BTK inhibitor (BTKi) ibrutinib could potentiate tumor-cell killing. We conducted an investigator-initiated phase 2 clinical trial to assess the efficacy of combined nivolumab and ibrutinib in patients with diffuse large B-cell lymphoma (DLBCL) RT and CLL. Patients included were ≥18 years of age with adequate hepatic and renal function. Patients received nivolumab every 2 weeks of a 4-week cycle for a maximum of 24 cycles. A standard dose ibrutinib was initiated from cycle 2 onward and continued daily until progression. For patients who were already on ibrutinib at the time of study entry, the same was continued while nivolumab was initiated. A total of 24 patients with RT with a median age of 64.5 years (range, 47-88) were enrolled. Ten patients (42%) had received prior treatment for RT and 13 patients (54%) had received a prior BTKi. A total of 10 patients (42%) responded with a median duration of response of 15 months. The median overall survival was 13 months. Four of 24 (17%) patients had checkpoint inhibition–related immunological toxicities. In the CLL cohort, 10 patients were enrolled, of whom 3 patients converted from partial to complete remission; 1 patient had a grade 2 immunological toxicity. Combined nivolumab and ibrutinib is an active regimen for patients with DLBCL RT with an overall response rate of 42%. Given the limited treatment options for patients with RT, checkpoint inhibition provides a potential therapeutic option. This trial is registered at www.clinicaltrials.gov as #NCT02420912.